# The Antiretroviral Pregnancy Registry

## The Purpose of the Antiretroviral Pregnancy Registry (APR)

A voluntary prospective, exposure-registration, observational study designed to collect and evaluate data on the outcomes of pregnancies exposed to antiretroviral (ARV)/antiviral (AV) products. The APR is intended to provide an early signal of any major teratogenic effect associated with a prenatal exposure to the products monitored through the Registry.

## How to Become a Reporter

- Contact the Registry by email, phone, or fax.
- An APR team member will collect your contact information and register your institution within APR's database.
- Once registered, you will receive a unique HCP ID, instructions for enrolling your eligible patients and Log IDs to keep your patient anonymous thus eliminating the need for informed consent.
- Health Care Providers (HCPs) that can report to APR include: physician, pharmacist, physician assistant, nurse practitioner, registered nurse, medical assistant, etc., as long as you have access to ARV/AV exposure and pregnancy outcome information.

## Enrolling a Patient in the Registry





**Email:**

SM_APR@APRegistry.com

**Website:**

www.APRegistry.com

**Phone:**

1-800-258-4263

(US / Canada toll-free)

+1-910-679-1598
(International)

**Fax:**

1-800-800-1052

(US / Canada toll-free)

+1-910-256-0637
(International)


**Scan to learn more about the APR**

## A Message From Dr. William R. Short, MD, MPH, FIDSA

**Associate Professor of Medicine and Obstetrics/Gynecology**

"Often, pregnant persons are excluded from clinical trials; therefore, it is critical that we collect prospective data on new antiretroviral (ARV) agents as they are FDA approved. The Antiretroviral Pregnancy Registry (APR) plays a critical role in filling this gap but is dependent on providers, like you, to report exposures. Do your part and contribute to evaluating ARV safety by reporting all exposures to the APR."

## Perinatal Guidelines Recommendation

According to the Perinatal Guidelines: **"Clinicians are encouraged to submit to the Antiretroviral Pregnancy Registry data for all patients who conceive while receiving ARV drugs or who receive ARV drugs during pregnancy."***

*Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/guidelines-perinatal.pdf. Accessed 06May2024[Page C-36].